ArticleBMC pregnancy and childbirth2025
Predictive value of Glycosylated Fibronectin (GlyFn)/Placenta Growth Factor (PlGF) ratio for high-risk pregnancies: a cohort study.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreeclampsia (PE) is a hypertensive disorder in pregnancy involving multiple organ systems, primarily due to impaired placental development during the first trimester. Reduced Placenta Growth Factor (PlGF) and elevated Glycosylated Fibronectin (GlyFn) levels reflect these pathological changes. Combining these biomarkers into a ratio may enhance PE prediction in high-risk pregnancies.
objectiveTo evaluate the GlyFn/PlGF ratio measured at 20-28 weeks of gestation as a predictor of preeclampsia in high-risk pregnancies across four hospitals in West Java, Indonesia, from April-October 2024.
methodsThis prospective cohort study involved 54 high-risk pregnant women. The GlyFn/PlGF ratio was analyzed at 20-28 weeks to assess predictive accuracy for PE.
resultsSignificant differences were noted between PE and non-PE groups in pre-pregnancy weight (65.54 ± 12.69 vs. 58.53 ± 7.85 kg), BMI (45.52 ± 53.73 vs. 19.84 ± 2.97), and systolic blood pressure (153.50 ± 19.42 vs. 100.80 ± 15.38 mmHg) (P > 0.05). Risk factors such as prior PE (P = 0.01), diabetes mellitus (P = 0.03), and gestational hypertension (P = 0.02) were more frequent in the PE group. A GlyFn cutoff of 34.31 ng/mL showed a 2.5-fold increased PE risk (sensitivity: 83.33%, specificity: 66.67%, AUC: 0.8071). A PlGF cutoff of 26.72 pg/mL was associated with a 6.8-fold increased risk (sensitivity: 72.22%, specificity: 97.22%, AUC: 0.9147). The GlyFn/PlGF ratio cutoff of 1.288 indicated a 28-fold higher PE risk (sensitivity: 77.78%, specificity: 97.37%, AUC: 0.9244).
conclusionThe GlyFn/PlGF ratio outperforms individual biomarkers in predicting preeclampsia in high-risk pregnancies, offering a valuable tool for early risk identification and timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.